Barclays Maintains Overweight on Regenxbio, Lowers Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang maintains an Overweight rating on Regenxbio (NASDAQ:RGNX) but lowers the price target from $55 to $50.
August 05, 2024 | 11:52 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barclays analyst Gena Wang maintains an Overweight rating on Regenxbio but lowers the price target from $55 to $50.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some tempered expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100